In this week’s Video Forum, Joe DePinto, head of cell, gene and advanced therapies at McKesson, talks about the company’s new InspiroGene division and the impact it is expected to have on the biotech marketplace. Precision dispensing and patient management, the product pipeline for advanced therapies, and recent research from InspiroGene were among the topics discussed.
Video Forum: Joe DePinto, McKesson
New division takes aim at cell and gene therapies.
Related
Latest
Senate finance leaders introduce bipartisan PBM Reform, NACDS hails move and calls for swift passage
Legislation aims to curtail harmful PBM middlemen tactics that inflate drug costs and force pharmacies to close.
NCPA urges Congress to pass Crapo-Wyden PBM Reforms
Wide bipartisan support means no more excuses, says NCPA.
Kroger Q3 earnings beat estimates
Gains in eCommerce and private-label brands offset charges tied to automated fulfillment network; grocer lifts earnings guidance for the year.
CVS Health to pay $37.76 million over insulin pen overbilling allegations
Settlement resolves decade-long False Claims Act violations tied to premature refills and inaccurate reporting to federal health care programs.